Withdrawal Notice: Recent Discovery for Inhibitors Targeting in SARS-CoV-2 and Developed anti-NCP

Abstract

: The current emergency in China causes by the spreading 2019-nCoV is to create a very critical condition in human society known as COVID-19. This virus is very complex, transfer human-to-human, belonging to the family coronaviridea and genera betacoronavirus. By the infection, common symptoms have been observed like a sudden high fever in between 1 to 9 days and some of the problem in the neck region with starting infection day and then this infection spread into the lungs causes novel coronavirus pneumonia (NCP) and kidney failure. At this time, to find a solution to the problem, a lot of researchers is working together to solve this problem. According to the WHO, more than 3588773 cases were confirmed around globally by the infected COVID-19. Many of the receptor protein of the SARS-CoV-2 and target proteins of the human cell is responsible for endocytosis like Mpro or 3CLpro, RNA polymerase, spike protein etc. These proteins play a vital role in the life cycle of SARS-CoV-2. As anti-COVID-19 drugs, many compounds were designed by computational methods to inactive of the receptor protein has been reported. Some of the drugs are ongoing under trail, and these drugs will be shows strong potent activity against this virus in the future. In this study represent about the synthetic and computational designed approach drugs and compounds for the inhibit receptor of SARS-CoV-2. This review will be helpful to find a new approach drug as an inhibitory receptor of SARS-CoV-2 structure and their life cycle, and also be helpful to identify and synthesis of effective drug and vaccine candidates for anti-novel coronavirus. We will be able to fight this coronavirus with our new time in this world.